What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

被引:79
|
作者
Petrini, P [1 ]
机构
[1] Karolinska Hosp, Dept Paediat, S-17176 Stockholm, Sweden
关键词
haemophilia; prophylaxis; trough level;
D O I
10.1046/j.1365-2516.2001.00471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1-2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988-98 with severe haemophilia A or B needed a Port-a-Cath(R) for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0-4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 50 条
  • [31] A single centre experience of prophylactic rFVIIA in paediatric patients with severe haemophilia and inhibitors
    Breen, K. A.
    Kavanagh, M.
    Kelly, I
    Nolan, B.
    Regan, I
    McMahon, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 835 - 835
  • [32] F8 gene dosage defects in atypical patients with severe haemophilia A
    Vencesla, A.
    Baena, M.
    Garrido, R. P.
    Nunez, R.
    Velasco, F.
    Rosell, J.
    Villar, A.
    Jimenez-Yuste, V.
    Baiget, M.
    Tizzano, E. F.
    HAEMOPHILIA, 2012, 18 (05) : 708 - 713
  • [33] COST-EFFECTIVENESS OF EFTRENONACOG ALFA IN TREATMENT OF SEVERE HAEMOPHILIA B PATIENTS IN TURKEY
    Tatar, M.
    Kamaci, E.
    Alhagiri, E.
    Alghamdi, M.
    VALUE IN HEALTH, 2023, 26 (12) : S162 - S162
  • [34] Endothelial Function in Patients with Severe and Moderate Haemophilia A and B
    Boehmert, Stephanie
    Schubert, Ralf
    Fichtlscherer, Stephan
    Alesci, Sonja
    Miesbach, Wolfgang
    HAMOSTASEOLOGIE, 2019, 39 (02): : 195 - 202
  • [35] HLA B27 in patients with severe haemophilia
    Solis, R.
    Castro, S.
    Zurita, E.
    Lopez, F.
    Ramon, E.
    Rueda, M.
    Nemer, J.
    HAEMOPHILIA, 2008, 14 : 28 - 29
  • [36] PERITONEAL DIALYSIS AND HEMODIALYSIS. WHAT FACTORS SHOULD INFLUENCE TREATMENT CHOICE?
    Toledo-Cuenca, Soledad
    Gonzalez-Cervantes, Sergio
    Garcia-Garcia, Esther
    REVISTA ROL DE ENFERMERIA, 2018, 41 (01): : 14 - 20
  • [37] Modern treatment options for von Willebrand disease and haemophilia B - What are the benefits for the patients?
    Giangrande, Paul
    von Depka, Mario
    Kessler, Craig M.
    Kannicht, Christoph
    Ljung, Rolf
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (03) : 5 - 14
  • [38] Treatment related factors and inhibitor development in children with severe haemophilia A
    Maclean, P. S.
    Richards, M.
    Williams, M.
    Collins, P.
    Liesner, R.
    Keeling, D. M.
    Yee, T.
    Will, A. M.
    Young, D.
    Chalmers, E. A.
    HAEMOPHILIA, 2011, 17 (02) : 282 - 287
  • [39] COST IMPACT OF A NOVEL PROPHYLACTIC TREATMENT FOR HAEMOPHILIA A PATIENTS WITH INHIBITORS IN THE UK
    Roberts, G.
    Chu, P.
    Hampton, R.
    VALUE IN HEALTH, 2017, 20 (09) : A551 - A551
  • [40] Prophylaxis or on demand treatment for adult patients with severe haemophilia?
    Neme, Daniela
    Del Rio, Lina
    Cocca, Andrea
    Chirino, Walter
    HAEMOPHILIA, 2023, 29 : 12 - 13